BRIBF
Price:
$0.1832
Market Cap:
$699.08M
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of va...[Read more]
Industry
Biotechnology
IPO Date
2022-01-21
Stock Exchange
PNK
Ticker
BRIBF
According to Brii Biosciences Limited’s latest financial reports and current stock price. The company's current ROE is -8.88%. This represents a change of 280.85% compared to the average of -2.33% of the last 4 quarters.
The mean historical ROE of Brii Biosciences Limited over the last ten years is 2.14%. The current -8.88% ROE has changed -514.36% with respect to the historical average. Over the past ten years (40 quarters), BRIBF's ROE was at its highest in in the March 2021 quarter at 31.88%. The ROE was at its lowest in in the September 2021 quarter at -18.11%.
Average
2.14%
Median
-5.61%
Minimum
-123.25%
Maximum
84.35%
Discovering the peaks and valleys of Brii Biosciences Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 84.35%
Minimum Annual Increase = -277.61%
Minimum Annual ROE = -123.25%
Year | ROE | Change |
---|---|---|
2023 | -5.61% | -60.44% |
2022 | -14.17% | -88.50% |
2021 | -123.25% | -277.61% |
2020 | 69.40% | -17.73% |
The current ROE of Brii Biosciences Limited (BRIBF) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-47.68%
5-year avg
2.14%
10-year avg
2.14%
Brii Biosciences Limited’s ROE is less than Avalo Therapeutics, Inc. (42.52%), less than Alzamend Neuro, Inc. (550.92%), greater than Virax Biolabs Group Limited (-115.10%), less than Kiromic BioPharma, Inc. (327.18%), greater than Benitec Biopharma Inc. (-60.28%), greater than Cardio Diagnostics Holdings, Inc. (-258.81%), greater than Sigilon Therapeutics, Inc. (-74.73%), greater than Sonnet BioTherapeutics Holdings, Inc. (-383.41%), greater than ZyVersa Therapeutics, Inc. (-25512.50%), greater than X4 Pharmaceuticals, Inc. (-32.51%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than 89bio, Inc. (-59.58%), greater than Cabaletta Bio, Inc. (-50.10%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Mirum Pharmaceuticals, Inc. (-41.22%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than Axsome Therapeutics, Inc. (-234.35%), less than Incyte Corporation (0.78%), less than ImmunoGen, Inc. (5.04%), less than Sarepta Therapeutics, Inc. (11.83%), less than ACADIA Pharmaceuticals Inc. (25.83%),
Company | ROE | Market cap |
---|---|---|
42.52% | $92.18M | |
550.92% | $6.47M | |
-115.10% | $7.47M | |
327.18% | $1.47M | |
-60.28% | $268.85M | |
-258.81% | $40.84M | |
-74.73% | $56.22M | |
-383.41% | $4.27M | |
-25512.50% | $2.70M | |
-32.51% | $98.92M | |
-32.76% | $492.65M | |
-59.58% | $933.60M | |
-50.10% | $114.37M | |
-32.52% | $1.99B | |
-41.22% | $2.02B | |
-88.42% | $188.22M | |
-22.40% | $1.28B | |
-49.25% | $18.30M | |
-234.35% | $4.22B | |
0.78% | $13.47B | |
5.04% | $8.73B | |
11.83% | $11.64B | |
25.83% | $2.84B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Brii Biosciences Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Brii Biosciences Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Brii Biosciences Limited's ROE?
How is the ROE calculated for Brii Biosciences Limited (BRIBF)?
What is the highest ROE for Brii Biosciences Limited (BRIBF)?
What is the 3-year average ROE for Brii Biosciences Limited (BRIBF)?
What is the 5-year average ROE for Brii Biosciences Limited (BRIBF)?
How does the current ROE for Brii Biosciences Limited (BRIBF) compare to its historical average?